MedX Health Corp. Announces CE Mark for Its MOLEMATE(TM)/SIMSYS(TM) Skin Cancer Imaging Systems

MedX Health Corp. ("MedX" or the "Company") (TSX VENTURE:MDX), a leader in skin
cancer imaging and diagnostics, announced receipt of a CE Mark from Conformite
Europeenne, which allows the Company to market its MoleMate and SIMSYS systems
in Europe to dermatologists and to expand further its pharmacy-based sales
channel. 


"Adding CE approval to our existing Health Canada and FDA approvals is a very
positive development" noted Rob von der Porten, President and CEO. "This allows
us to expand our sales effort into all countries in the European Union. While
skin cancer is the one of the most curable cancers if caught early, statistics
indicate that it is one of the least screened-for cancers; our technology can be
rolled-out to many health related facilities, including community health
centers, clinics and pharmacies, thereby facilitating early screening which
could save lives, but also reduce the number of unnecessary biopsies, two
outcomes which would cut the burgeoning costs of health care as well as reduce
patient anxiety and suffering."


"Over the past years, (MoleMate/SIMSYS) has been a great tool at reassuring
patients that a lesion was benign if my exam alone was not enough to comfort
them," says Dr. R.H. Falcon, Dermatologist, New York, NY. "Surprisingly in a few
patients that I was worried clinically had Melanoma, who for whatever reason did
not want a biopsy, I have been able to show them on the device the signs of the
cancerous lesions and convince them to let me remove it. I can honestly say in
the years since I have the device, I have been able to save some lives by
convincing a patient they needed a lesion removed and were only convinced once
they saw the image on the screen."


Leading European Dermatologist, Giuseppe Argenziano, M.D. recently conducted an
internal study to evaluate the efficacy and accuracy of the MedX SIAscopy
technology and device, notes "The MedX MoleMate system is an advanced screening
device used in the early detection of skin cancer (melanoma) and precancerous
skin lesions. The results of this study have been submitted and accepted for
publication soon to be released in the Skin Research and Technology Journal."
Dr. Argenziano is a leading expert in Dermatascopy skin evaluation techniques
and has been following the development of the SIAscopy technology over the past
8 years. 


Among the sophisticated equipment used by University of California Irvine
Melanoma Center, physicians are currently using SIMSYS-MoleMate, "one of the
most advanced melanoma imaging systems in the world. For patients with many
moles, this computer imaging can make a big difference, it decreases the number
of biopsies needed, so they won't look like a pincushion," explained Dr. James
G. Jakowatz, surgical oncologist and UC Irvine Melanoma Center director, Dr.
Janellen Smith, UC Irvine dermatologist and co-director of the Pigmented Lesion
Program, UC Irvine.


About MedX Health Corp. 

MedX is an ISO 13485 medical device manufacturing company, headquartered in
Mississauga, Ontario, and is a global leader in skin cancer imaging and
diagnostic devices and quality low level laser and light therapy technologies.
MoleMate and SIMSYS skin cancer imaging and diagnostic systems offer significant
advancement in the early detection of potentially life threatening moles and
lesions. MoleMate and SIMSYS rapidly provide accurate images of the pigment,
blood, and collagen up to 2mm below the skin to assist in the assessment of
moles and lesions. This proven skin cancer related device is used for early
diagnoses on various skin histology which includes Basal Cell Carcinoma,
Squamous Cell, Hemangioma and the most deadly, Melanoma. MoleMate and SIMSYS are
FDA, Health Canada and CE Mark approved. For a complete profile of MedX Health
Corp. and its products visit www.medxhealth.com.


This press release contains certain forward-looking statements within the
meaning of applicable Canadian securities legislation. These forward-looking
statements involve certain risks and uncertainties that could cause actual
results to differ, including, without limitation, the company's limited
operating history and history of losses, the inability to successfully obtain
further funding, the inability to raise capital on terms acceptable to the
company, the inability to compete effectively in the marketplace, the inability
to complete the proposed acquisition and such other risks that could cause the
actual results to differ materially from those contained in the company's
projections or forward-looking statements. All forward looking statements in
this press release are based on information available to the company as of the
date hereof, and the company undertakes no obligation to update forward-looking
statements to reflect events or circumstances occurring after the date of this
press release.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this press release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
MedX Health Corp.
Robert von der Porten
President and CEO
905 670 4428
investor@medxhealth.com
www.medxhealth.com
Medx Health (TSXV:MDX)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024